Meta description: A completed taVNS trial assessing stress reduction in university students raises regulatory attention and signals need for future outcome data.
On February 19, 2026 the record shows a completed study testing a device based taVNS for reducing psychological distress, stress and perceived stress in a university population. The sponsor is Egas Moniz Cooperativa de Ensino Superior CRL. The trial uses a taVNS device and a sham comparator and is registered on ClinicalTrials.gov as NCT07411846. The source text indicates this may be a trial record or article extract and does not provide efficacy results in the extract.
In this article you will find anchor navigation to key sections that summarize the available information and its regulatory implications.
What changed in this protocol
The source text confirms a trial that uses a taVNS device with a sham control to study stress outcomes in university students. The intervention involves a non invasive neuromodulation delivered at the ear and targets psychological distress, stress and perceived stress as conditions. The sponsor name appears as Egas Moniz Cooperativa de Ensino Superior CRL, and the record status is Completed.
ClinicalTrials.gov provides the official record NCT07411846; the source text links to the page with the device related study. There are no efficacy results in the extract, so regulatory interpretation focuses on study existence, design and safety signals rather than outcomes.
How the trial was designed
The design elements recorded include a device taVNS and a sham comparator to assess feasibility and potential impact on stress related endpoints. The completed status indicates that data collection and study activities have ended, but no study results are included in the extract. The information provides a basis for future regulatory consideration should data become available for public dissemination.
Who is affected
The intended population consists of university students experiencing psychological distress. Findings from this line of inquiry may influence future research directions and potential regulatory pathways for neuromodulation devices evaluated in student populations, including considerations of consent, safety monitoring and post trial reporting.
Safety and regulatory implications
From a regulatory perspective the taVNS device requires careful labeling of its intended use as a stress reduction intervention and appropriate safety claims consistent with MDR Annex XIV style. The lack of efficacy data in the extract means no performance claims can be made at this time, and any future market submission would rely on complete trial results. The sponsor being a higher education institution suggests that subsequent regulatory actions may come from future data submissions and formal safety evaluations.
FAQ
- 1. What is taVNS? A non invasive ear based neuromodulation technique that aims to influence autonomic and stress responses.
- 2. What does Completed status mean? It means the study completed data collection and overall activities but does not provide efficacy outcomes in the source extract.
- 3. Where can I find more details? The official record is on ClinicalTrials.gov under NCT07411846; see the link in the opening text for access.
Conclusion and implications
The completed taVNS study for stress reduction in university students underscores ongoing interest in neuromodulation devices for mental health. Regulators will seek complete result data, safety analyses and clear labeling before considering any market action. Practitioners and sponsors should track forthcoming publications or regulatory filings that may arise from this record.
Disclaimer
This information is intended for professionals and does not constitute legal advice. It reflects the provided source text and should not be interpreted as regulatory guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07411846?term=medical+device